Cell Therapy, Gene Therapy & Genome Editing

Transformative therapies provide a significant, durable benefit and value for patient health outcomes, delivery of care, and overall health care spending. These therapies are aimed at serious and rare diseases where patients often have limited treatment options. Examples of transformative therapies include cellular and gene therapies, which are truly personalized medicines that target treatment to specific patient populations or subsets of patient populations.

Press Releases
September 2, 2020
Today, the Centers for Medicare and Medicaid Services finalized this year’s inpatient prospective payment system (IPPS) rule, which includes a new diagnosis-related group (DRG) to streamline reimbursements for providers administering CAR T-cell therapies to patients with cancer. Following CMS’…
February 15, 2019
BIO Executive Vice President for Health Policy Dan Durham issued the following statement regarding the CMS proposed decision memo for the CAR-T National Coverage Determination.
December 2, 2024
Today, the Biotechnology Innovation Organization (BIO) and the Council of State Bioscience Associations (CSBA) released new national and state-level data on the U.S. bioscience industry's economic performance, its impacts, and its geographic footprint.The report, "The U.S. Bioscience Economy:…
Genome Editing Toolkit

Genome editing represents one of the most promising areas of biotechnology, with the potential for transformative breakthroughs in both human health and agriculture. Find important resources and background materials to better understand these groundbreaking innovations and what is needed to ensure that society can harness the full potential. 

Genome Editing
Become an Advocate for Biotechnology
Become an Advocate for Biotechnology

Sign-up to join BIOAction, BIO's grassroots advocacy program. You will be notified about relevant policy issues where we need you to contact your lawmaker.